Sanofi’s Amcenestrant Disappoints in Phase 2 Breast Cancer Trial
Sanofi’s investigational cancer drug, amcenestrant, failed to improve progression-free survival for patients with advanced estrogen receptor-positive HER2-negative breast cancer in a phase 2 study.
The drug was evaluated as a monotherapy against physician’s choice of endocrine treatments in patients who had progressed on or after hormonal therapies.
An oral selective estrogen receptor degrader, amcenestrant binds to estrogen receptors in breast cancer cells to inhibit their function and prevent tumor cell growth.
The company will “continue to investigate amcenestrant in patients with earlier stages of breast cancer with different tumor profiles and where different standard-of-care treatments are used,” said John Reed, Sanofi’s head of research and development.